<unk>  is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS).<unk>  is the successor of Active Biotech's failed experimental immunomodulator linomide.
The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI).<unk>  seems to be able to reduce the MS disease activity on MRI. However, the response to a given dose was discrepant between both studies.
Phase III studies for MS started in December 2007. In 2011, Teva announced its clinical trials involving<unk>  had failed, being unable to significantly reduce relapses into MS among patients beyond a placebo. However, the final results of above-mentioned phase III trial proved oral<unk>  administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.
Laquinimod
Glatiramer
Atezolizumab
Fingolimod
Glatiramer acetate
Nebacumab
Tocilizumab
Riluzole